CITF Research Results

CITF Research Results2023-10-27T10:53:53-04:00

Seroprevalence provides an accurate measure of SARS-CoV-2 infection compared to PCR testing

A CITF-funded study, published in the CMAJ Open, found that seroprevalence data is a very useful mechanism to obtain accurate measures of the prevalence of SARS-CoV-2 infection in the population, and when compared to PCR testing which under detects the number of infections was more reflective of the true burden.

April 15, 2023|Geographic & priority populations|

Protocol: strength and duration of immune responses to COVID-19 vaccines in people living with chronic kidney disease (CKD)

This paper, published in the Canadian Journal of Kidney Health and Disease by CITF-funded researchers Drs. Matthew Oliver and Michelle Hladunewich (Sunnybrook Health Sciences Centre), presents the protocol for a new study aimed at characterizing the strength and duration of immune responses to COVID-19 vaccines in people living with chronic kidney disease (CKD).

April 3, 2023|Higher risk due to health conditions|

Establishing an immune protection threshold is essential to optimize and individualize SARS-CoV-2 vaccination

A CITF-funded study published in Transplantation aims to identify correlates of protection that would be necessary to safeguard against various SARS-CoV-2 variants. Researchers found that a binding antibody concentration of less than 752 binding antibody units (BAU/mL) resulted in poor immune protection against Omicron, whereas levels over 1357 BAU/ml resulted in 100% neutralization against Omicron.

April 3, 2023|Immune science|

Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in adults with IMIDs

A CITF-funded study, published in preprint and not yet peer-reviewed, demonstrates that third and fourth doses of vaccine sustain and broaden immune responses to SARS-CoV-2 in adults with immune-mediated inflammatory diseases (IMIDs). The authors conclude that this supports the recommendation for three- and four-dose primary series vaccine regimens in this population.

April 3, 2023|Higher risk due to health conditions|
Go to Top